We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 295

Pharma Companies May Benefit from Proposed Patent Law Changes in China; Public Comment Invited
  • Hogan Lovells
  • China
  • January 9 2019

On January 4, China’s National People’s Congress (NPC) released draft amendments to the Chinese Patent Law, proposing expanded and enhanced

Life Sciences: product regulation and liability in China
  • Ropes & Gray LLP
  • China, Global
  • January 7 2019

A structured guide to product regulation and liability laws in China

China proposes new draft laws on drug and vaccine management
  • Herbert Smith Freehills LLP
  • China
  • January 2 2019

In October 2017, China’s Communist Party and the State Council issued Opinions on Deepening the Reform of Evaluation and Approval System and

Tracking Trends in Global Collaboration and Licensing Agreements
  • McDermott Will & Emery
  • China
  • December 26 2018

For decades, partnering was the lifeblood of large pharma and small biotech alike. Today, small biotechs increasingly have the upper hand as

SAMR revamps procedural penalty rules
  • AnJie Law Firm
  • China
  • November 29 2018

The newly established State Administration for Market Regulation recently embarked on its first major overhaul of procedural rules by publishing the

Clarification of the role of China National Medical Products Administration
  • CMS, China
  • China
  • October 9 2018

The State Council of the PRC released a document on 11 September 2018, clarifying the role of the recently restructured National Medical Products

Review of recent listings of biotechnology companies by way of Chapter 18A of the Hong Kong Main Board Listing Rules
  • King & Wood Mallesons
  • Hong Kong
  • September 28 2018

Since the new regime for listing of innovative companies was put in place four months ago, there has been a number of biotechnology companies seeking

China Accepts Overseas Clinical Trial Data to Expedite Drugs Registration in China
  • CMS, China
  • China
  • September 3 2018

On 6 July 2018, the China Food and Drug Administration ("CFDA") issued the Technical Guiding Principles for the Acceptance of the Overseas Clinical

CDE solicitation on the list of urgently needed drugs
  • CMS, China
  • China
  • September 3 2018

The Centre for Drug Evaluation ("CDE") of the CNDA released the List of Overseas Drugs in Urgent Need ("List") on 8 August 2018. The List was open for

Rules of accepting overseas clinical trial data
  • CMS, China
  • China
  • September 3 2018

CNDA issued the Guiding Technical Principles for the Acceptance of Overseas Clinical Trial Data of Drugs ("Principles") on 10 July 2018, which